![Research Podcast Cover](/sites/default/files/styles/podcast_image/public/images/podcast/Research_Podcast_Cover_3000X3000_10.12.23.jpg?h=f405c703&itok=1Q_k8SJk)
![Research Podcast Cover](/sites/default/files/styles/podcast_image/public/images/podcast/Research_Podcast_Cover_3000X3000_10.12.23.jpg?h=f405c703&itok=1Q_k8SJk)
Evidence supports that dysfunction in the homeostasis of iron and other elements likely contributes to the pathophysiological mechanisms of Parkinson's disease, but we have yet to develop suitable elemental biomarkers for use in diagnosing and monitoring the progression of Parkinson's disease. Dr. Paul Lingor discusses his work in this area to identify patterns of bioelements in CSF that could serve as PD biomarkers. Beyond CSF, he is also examining tear fluid as a potential biomarker source that is easier to collect. In addition to work on biomarkers, Paul has been involved in developing and evaluating new treatments for Parkinson's disease. In this episode, he discusses an ongoing phase II clinical trial evaluating the ROCK inhibitor Fasudil, as well as research examining combinations of advanced therapies for people with later-stage Parkinson's disease. Paul is Professor of Neurology at the Technical University of Munich and head of the outpatient clinics for motor neuron disease and co-head of the outpatient clinics for Parkinson’s disease.
This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.
Rather listen on-the-go? Subscribe to The Parkinson’s Research Podcast: New Discoveries in Neuroscience on iTunes or through any podcast app on your smartphone or tablet.
View the transcript of this podcast.
You can learn more about the many resources The Michael J. Fox Foundation offers to researchers here.